RILEXINE®
(Cephalexin) Chewable Tablets for Dogs

Antimicrobial for Oral Use in Dogs only

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: RILEXINE® Chewable Tablets are a new, biconvex tablet supplied in a sizes containing 150 mg, 300 mg, and 600 mg of cephalexin. Cephalexin is a cephalosporin, beta-lactam, broad spectrum antibiotic. The full chemical name for cephalexin is 7-[D-(+)
aminos-4-phenylacetamido]-3-methyl-1-cephem-4-carboxylic acid monohydrate.

INDICATIONS: For the treatment of secondary bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

DOSEAGE AND ADMINISTRATION: The recommended dose is 22 mg/kg (10 mg/lb) of body weight twice daily for 28 days. 

Adult dogs: Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to cephalexin. Therapy with RILEXINE Chewable Tablets may be initiated before results of these tests are known, once the results become available, antimicrobial therapy should be adjusted accordingly. If acceptable response to treatment is not observed, then the diagnosis should be re-evaluated and appropriate alternative therapy considered.

SIDE EFFECTS: RILEXINE Chewable Tablets may be associated with transient increases in serum aminotransferases, prolonged prothrombin time (PT) and partial thromboplastin time (PTT), anemia, hypoprothrombinemia, thrombocytopenia, with cephalosporin therapy include neutropenia, myelotoxicity, thereby creating a toxic effect. Occasionally, cephalosporins have been associated with time-dependent killing effects. Accordingly, the pharmacodynamic (PD) target time above MIC (T > MIC). For staphylococcal infections, the goal for time above MIC is 40% of the dosing interval (which translates to 4.8 hrs for a BID dose). The time above the minimum inhibitory concentration (MIC) for Staphylococcus pseudintermedius is 2 µg/mL. Plasma drug concentrations were normalized to exactly 22 mg/kg dose and corrected for 10% protein binding (protein binding observed in canine plasma) to the controls. These changes were minimal and the values remained within expected historical control ranges. There were several decreases in total protein (in the 110 mg/kg three times a day group and/or globulin in the 22.66, and 110 mg/kg three times a day groups compared to the controls. These changes resulted in occasional increases in albumin/globulin ratios. Although a drug effect cannot be ruled-out, these changes were not clinically relevant.

A mild prolongation in prothombin time (PT) was observed in the 22 mg/kg three times a day group. This was not considered clinically relevant due to the small change that remained within the reference range.

One dog in the 110 mg/kg three times a day group had moderate amounts of bilirubinuria at the end of the study. After dosing, cephalexin was well absorbed into systemic circulation of the treated dogs. Within gender and dose groups, peak plasma drug concentrations were generally higher than the Week 4 and 12 mean trough concentrations (between 0.9 and 3.6-fold difference). The geometric mean plasma cephalosporin trough concentration following three times daily administration of the 110 mg/kg dose was 11.2 µg/mL compared to 2.6 µg/mL. Following 22 mg/kg and 66 mg/kg, respectively. At Week 12. Geometric mean plasma cephalosporin trough concentrations following administration of 22 mg/kg twice a day increased to 11.2 µg/mL and 10.5 µg/mL at Weeks 4, 8, and 12, respectively.

STORAGE INFORMATION: Store at 20°C-25°C (68°F-77°F), with excursions permitted between 15°C-30°C (59°F-86°F).

HOW SUPPLIED: RILEXINE® (cephalexin) Chewable Tablets are supplied 150 mg, 300 mg, and 600 mg tablets packaged in bottles of 100 tablets.

NADA 141-326. Approved by FDA.

Distributed by: Virbac Animal Health, Inc. Fort Worth, TX 76137 USA

RILEXINE® is a registered trademark of Virbac S.A.